Catalog No.
Product Name
Application
Product Information
Citations
-
IL-17 Modulator
IL-17 modulator 10 is a potent inhibitor of the IL-17 signaling pathway, demonstrating an IC50 of 0.71 μM in HTRF assays that evaluate the binding of IL-17A to IL-17RA. This compound is particularly relevant for research focused on autoimmune and inflammatory diseases, providing valuable insights into therapeutic interventions targeting IL-17-mediated pathways. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-25 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting an IC50 of 0.55 μM and a binding affinity (Kd) of 0.50 μM. This compound effectively activates the Nrf2 pathway, leading to the reduction of reactive oxygen species (ROS) and pro-inflammatory cytokines such as IL-1β and IL-6. Keap1-Nrf2-IN-25 has demonstrated protective effects in models of colitis, particularly against DSS-induced inflammation, making it a valuable tool for research in oxidative stress and inflammatory diseases. -
IL-17 Modulator
IL-17 Modulator 2 is an orally active compound that targets the IL-17 pathway. It is effective in significantly reducing levels of pro-inflammatory cytokines, including IL-6 and IFN-γ, while also decreasing edema. This reagent is suited for research applications related to arthritis and other inflammatory conditions. -
IL-1 Inhibitor
E5090 is an orally active inhibitor of IL-1 generation, acting through its conversion in vivo to the active deacetylated form, DA-E5090. This compound exhibits significant anti-inflammatory properties, making it valuable for studies related to inflammation and immune response modulation. E5090 is useful in various immunology research applications, particularly in understanding the role of IL-1 in disease states. -
IL-17A Inhibitor
Acetyl zingerone is an IL-17A inhibitor that exhibits potent anti-inflammatory and antioxidant activities. This compound plays a crucial role in protecting melanocytes from DNA damage by inhibiting matrix metalloproteinases and downregulating IL-17A target gene expression. Acetyl zingerone is valuable for research focused on inflammatory skin conditions and mechanisms of cellular protection. -
Inflammatory Cytokine Inhibitor
JTE-607 free base is a selective inhibitor of inflammatory cytokine synthesis, targeting the Cleavage and Polyadenylation Specificity Factor 3 (CPSF3). This compound effectively reduces the production of key inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-8, and IL-10, in LPS-stimulated human peripheral blood mononuclear cells (PBMCs), achieving IC50 values of 11, 5.9, 8.8, 7.3, and 9.1 nM, respectively. JTE-607 free base demonstrates potential utility in research aimed at understanding and mitigating inflammatory responses, particularly in the context of endotoxin shock. -
Anti-inflammatory Agent
Polyandric acid A is a clerodane diterpenoid identified for its anti-inflammatory properties. It is derived from the Australian medicinal plant D. polyandra and has been shown to inhibit the secretion of pro-inflammatory cytokines. This compound has potential applications in research focused on inflammation-related pathways and therapeutic interventions for inflammatory diseases. -
IL-1/β-transferase Inhibitor
Pentenocin B is an IL-1/β-transferase inhibitor that selectively targets the interleukin-1 signaling pathway. This compound exhibits weak inhibitory activity against IL-1 and β-transferase, which are crucial in mediating inflammatory responses. Pentenocin B is useful for research applications focused on inflammation and related signaling mechanisms. -
IL-2 secretion inhibitor
BC12-4 is a potent inhibitor of interleukin-2 (IL-2) secretion, primarily acting on immune cell signaling pathways. This compound exhibits immunomodulatory activity, making it valuable in the study of cytokine regulation and immune responses. BC12-4 is suitable for research applications focused on autoimmune diseases, transplantation, and cancer immunotherapy. -
Anti-inflammatory effect
Hericene A is a phenolic compound derived from Hericium erinaceus, demonstrating potent anti-inflammatory activity. It effectively modulates cytokine secretion, exhibiting moderate inhibition of TNF-α, IL-6, and nitric oxide (NO). This compound is valuable for research into inflammatory pathways and potential therapeutic applications in inflammatory diseases. -
IL-1/β-transferase Inhibitor
Pentenocin A is an inhibitor of IL-1β-transferase, also known as interleukin-1 converting enzyme (ICE). This compound displays weak inhibitory activity against the processing of pro-inflammatory cytokine IL-1β, making it useful for studies related to inflammation and immune response. Its applications can extend to research exploring pathways involved in cytokine maturation and signaling, contributing to the understanding of various inflammatory diseases. -
Anti-inflammatory Agent
RPR-106541 is a 17-thiosteroid that functions primarily as an anti-inflammatory agent by exerting potent glucocorticosteroid activity. It has been shown to influence carbohydrate and lipid metabolism, making it relevant for research in metabolic disorders and inflammatory conditions. This compound is useful for studies investigating the mechanisms of inflammation and the modulation of metabolic pathways. -
Anti-inflammatory Agent
CK-17 is a potent anti-inflammatory agent that exhibits oral bioactivity. It effectively inhibits ocular inflammation induced by lens protein, endotoxin, and IL-1, demonstrating approximately twice the potency of Prednisolone in mitigating IL-1-induced responses. This compound serves as a valuable tool for researchers investigating inflammation pathways and potential therapeutic interventions in ocular diseases. -
Anti-inflammatory Pterocarpan
1,11b-Dihydro-11b-hydroxymedicarpin is a pterocarpan derivative known for its anti-inflammatory properties. This compound exerts its biological activity by activating the Notch and Wnt canonical signaling pathways, promoting bone healing and mitigating the effects of arthritis. In preclinical models, it inhibits the expansion of TH17 cells and reduces pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17A, while simultaneously enhancing the anti-inflammatory cytokine IL-10. These characteristics make it a valuable reagent for research applications focused on inflammatory diseases and bone regeneration. -
IL-2 Inhibitor
Digitoxigenin-3-O-β-D-quinovoside is a potent interleukin-2 (IL-2) inhibitor, exhibiting an IC50 value of 52 nM. This cardiac glycoside is derived from the plant Elaeodendron australe var. integrifolium. It is useful in research applications focused on immune modulation and the investigation of IL-2 signaling pathways, providing valuable insights into related therapeutic areas. -
IL-1β Inhibitor
Shegansu B is a potent inhibitor of IL-1β, demonstrating significant inhibition of IL-1β expression in LPS-induced THP-1 cells, achieving an inhibition rate of 64.74%. This compound exhibits noteworthy anti-inflammatory activity, making it a valuable tool for research applications focused on inflammation and immune response modulation. Its selective targeting of IL-1β positions Shegansu B as an important reagent for studies aimed at understanding inflammatory processes and potential therapeutic interventions. -
Stable Isotope
Tacrolimus-13C,d2 is a stable isotope-labeled form of Tacrolimus, a macrocyclic lactone that targets FK506 binding protein (FKBP). This compound forms a complex that inhibits calcineurin phosphatase activity, thereby blocking T-lymphocyte signal transduction and interleukin-2 (IL-2) transcription. Its potent immunosuppressive properties make it valuable for research in immunology and transplantation studies. -
CD45/CD148 Tyrosine Phosphatase Inhibitor
RWJ-60475 is a selective inhibitor of CD45 and CD148 tyrosine phosphatases, exhibiting an IC50 of 3.3 μM. By inhibiting these phosphatases, RWJ-60475 disrupts the phagocytic activity of macrophages, effectively blocking the invasion of Legionella pneumophila and the subsequent transport of effector proteins. This compound is valuable for research applications focused on anti-infection strategies that target host cellular factors. -
Anti-inflammatory Agent
Corylin is an orally active flavonoid that functions as an anti-inflammatory agent, primarily targeting IL-6-induced STAT3 signaling. It exhibits multiple biological activities, including anticancer effects and the modulation of hyperlipidemia and insulin resistance. Additionally, Corylin promotes adipocyte browning and enhances lipolysis through SIRT1 or β3-AR-dependent pathways, making it a valuable tool for research in metabolic disorders and inflammation. -
PGE2 Metabolite
15-keto-Prostaglandin E2 is a metabolite of prostaglandin E2 that primarily targets and inhibits STAT3 activation through binding to the Cys259 residue. This compound has been shown to inhibit the growth and progression of breast cancer cells while activating PPAR-γ, promoting fungal growth. Additionally, 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development, resulting in a decreased surface area of the glomerular filtration barrier, highlighting its importance in developmental biology and cancer research. -
CXCR4/STAT3 Inhibitor
Minecoside is a potent inhibitor of the CXCR4 receptor and STAT3 signaling pathway. It demonstrates significant anticancer and anti-inflammatory activities by downregulating CXCR4 expression and suppressing STAT3 activation, which leads to the inhibition of CXCL12-induced cellular invasion. Minecoside has been shown to effectively hinder cancer metastasis and enhance apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
Anti-inflammatory Agent
Bellidifolin is an orally active anti-inflammatory agent that demonstrates antiproliferative and antioxidant properties. It modulates crucial signaling pathways, including STAT3, PI3K-Akt, mTOR, and BRD4, while inhibiting the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exhibits significant antifibrotic effects, and offers protective benefits to the heart, liver, and nervous system. This compound is valuable for research into diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy, and ischemic cranial nerve injury. -
mPGES-2 Inhibitor
SZ0232 is a selective inhibitor of microsomal prostaglandin E synthase-2 (mPGES-2), effectively reducing the production of prostaglandin E2 (PGE2) and downregulating the PGE2-EP4 signaling pathway. This inhibition disrupts the β-catenin/STAT3/c-Myc proliferation cascade, demonstrating significant effects on the abnormal proliferation of cyst epithelial cells. SZ0232 serves as a valuable tool for investigating autosomal dominant polycystic kidney disease (ADPKD) in both in vitro and in vivo research models. -
Anti-Inflammatory Agent
MMPP is an anti-inflammatory agent that primarily targets the inhibition of STAT3 activity. It effectively prevents lipopolysaccharide (LPS)-induced mortality by modulating the inflammatory response. This compound is useful in research focused on understanding the mechanisms of inflammation and developing therapeutic interventions for inflammatory diseases. -
Anti-inflammatory Agent
Anti-inflammatory agent 92 is a porphyrin derivative that functions as an anti-inflammatory agent. This compound demonstrates significant anti-inflammatory properties, particularly in alleviating ulcerative colitis by inhibiting the STAT3-EPHX2 signaling pathway. It is a valuable tool for research into inflammation-related disorders and therapeutic interventions. -
Anti-inflammatory Agent
Fluorofenidone is an orally active anti-inflammatory agent that exhibits anti-fibrotic and antioxidant properties. It functions by downregulating ACSL4 expression, upregulating GPX4, and inhibiting the NF-κB signaling pathway, thereby alleviating inflammation and fibrosis. In preclinical models, Fluorofenidone has demonstrated efficacy in ameliorating cholestasis and fibrosis by modulating the hepatic Erk/Egr-1 signaling and TGFβ1/Smad pathways. This compound is particularly relevant for research into chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF), and non-small cell lung cancer (NSCLC). -
Anti-CD26 Antibody
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody that acts by inducing nuclear translocation of CD26 via the caveolin pathway. This antibody exhibits significant anti-proliferative effects on tumor cells by delaying the G2/M cell cycle transition. Additionally, YS110 is capable of inhibiting the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the interaction between MERS CoV S1 and CD26. It is a valuable tool for research applications in cancer biology and viral infections, including studies related to malignant mesothelioma and MERS. -
mTOR Inhibitor
Rapamycin-d3 is a deuterium-labeled analog of Rapamycin, a highly potent and selective inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 0.1 nM in HEK293 cells. It functions by binding to FKBP12, leading to allosteric inhibition of mTORC1. This compound is notable for its roles in autophagy activation and immunosuppression, making it valuable for various research applications including cancer biology, metabolic disorders, and studies of cellular growth and proliferation. -
FKBP12 Targeting AUTAC
AUTAC2 is an FKBP12-targeting autophagy-mediated degrader designed to promote selective degradation of specific proteins. This compound incorporates a p-Fluorobenzyl Guanine (FBnG) moiety and an SLF ligand, which non-covalently binds to FKBP12. AUTAC2 facilitates the targeted removal of proteins through the autophagy pathway, making it a valuable tool for research applications focused on protein homeostasis and cellular regulation. -
Stable Isotope
Carvedilol-d4 is a deuterated derivative of Carvedilol, a non-selective β/α-1 adrenergic receptor antagonist. It exhibits dose-dependent inhibition of lipid peroxidation with an IC50 value of 5 μM. Carvedilol acts as a multifaceted antihypertensive agent, demonstrating potential therapeutic applications in managing conditions such as angina and congestive heart failure. Additionally, it has been identified as an autophagy inducer and a modulator of the NLRP3 inflammasome, making it a valuable tool for research into cardiovascular and inflammatory diseases. -
Antiinflammatory Agent
Resolvin D3 (RvD3) is a bioactive mediator derived from docosahexaenoic acid (DHA) with potent anti-inflammatory properties. This compound plays a crucial role in resolving inflammation, making it particularly relevant for research into inflammatory conditions such as arthritis. By modulating immune responses, Resolvin D3 facilitates the resolution of inflammation, providing insights into therapeutic strategies for inflammatory diseases. -
Stable Isotope
Carvedilol-d3 is a deuterium-labeled analogue of Carvedilol, functioning primarily as a non-selective β/α-1 adrenergic receptor blocker. It exhibits significant biological activity by inhibiting lipid peroxidation in a dose-dependent manner with an IC50 value of 5 μM. This compound serves as a versatile antihypertensive agent and has potential applications in the treatment of angina and congestive heart failure. Furthermore, Carvedilol-d3 promotes autophagy and is known to inhibit the NLRP3 inflammasome, making it valuable for research involving inflammatory processes. -
Stable Isotope
Carvedilol-d5 is a deuterium-labeled analogue of Carvedilol, a non-selective β/α-1 adrenergic receptor blocker. It exhibits lipid peroxidation inhibition with an IC50 of 5 μM and serves as a versatile antihypertensive agent, showing potential in the treatment of angina and congestive heart failure. Additionally, Carvedilol functions as an autophagy inducer and inhibits the NLRP3 inflammasome, making it relevant for research in inflammatory pathways and cardiovascular health. -
COX Inhibitor
Indomethacin farnesil is a prodrug of indomethacin, primarily targeting cyclooxygenase (COX) enzymes. This potent, blood-brain barrier-permeable inhibitor exhibits nonselective activity against COX-1 and COX-2, with IC50 values of 18 nM and 26 nM, respectively. Indomethacin farnesil has been shown to disrupt autophagic flux by impairing lysosomal function, making it useful for investigating inflammatory pathways and autophagy-related processes in research applications. -
ULK1/ULK2 Inhibitor
SBP-5147 is a potent inhibitor of ULK1 and ULK2, exhibiting an IC50 of 2 nM for ULK1 and 53 nM for ULK2. This compound effectively inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagic flux, and downregulates the expression of key autophagy-related proteins ATG13 and ATG101. Additionally, SBP-5147 enhances MHC-I expression, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. Its mechanism of action makes SBP-5147 a valuable tool for research in non-small cell lung cancer and autophagy modulation. -
CATS Inhibitor
Z-Val-Val-Nle-diazomethylketone is a selective inhibitor of cathepsin S (CATS). This compound effectively reduces the IFNg-induced upregulation of MHCII molecules, specifically HLA-DR and Ii-p33/35, while promoting an increase in the Ii-p10 protein level. It is valuable for research into dermatological conditions such as psoriasis, atopic dermatitis, and actinic keratosis. -
Anti-inflammatory Agent
Fmoc-Leucine, an anti-inflammatory agent, functions primarily as a selective ligand for PPARγ, with a binding affinity (Ki) of 15 μM. It promotes both extracellular Ca2+ influx and intracellular Ca2+ release while exhibiting insulin-sensitizing effects with minimal fatogenic activity. This compound demonstrates unique self-assembly characteristics, forming transient gels, stable gels, or crystals/2D sheets under varying conditions. Fmoc-Leucine is valuable for research related to diabetes, colitis, and bladder cancer. -
Anti-inflammatory Agent
Hexadecanamide is a fatty acid amide that serves as an anti-inflammatory agent, exhibiting protective effects against Staphylococcus aureus and SARA-induced mastitis. It functions by suppressing S. aureus-mediated NF-κB activation and enhancing blood-milk barrier integrity. Additionally, Hexadecanamide activates PPARα and has been shown to improve sperm motility in vitro. This compound is relevant for research applications involving mastitis and asthenozoospermia. -
Anti-Inflammatory/Cancer Agent
Norathyriol is a natural metabolite derived from Mangifera, exhibiting significant anti-inflammatory and anticancer properties. It functions as a noncompetitive inhibitor of α-glucosidase with an IC50 value of 3.12 μM. Additionally, Norathyriol inhibits the peroxisome proliferator-activated receptors (PPARs) α, β, and γ, with IC50s of 92.8 μM, 102.4 μM, and 153.5 μM, respectively. This compound demonstrates a range of biological activities, including antioxidant, antimicrobial, and antibacterial effects, making it valuable for diverse research applications in inflammation and cancer therapeutics. -
Anti-inflammatory
1-O-Hexadecylglycerol serves as an anti-inflammatory agent by upregulating PPAR-γ expression and inhibiting prostaglandin E2 (PGE2) synthesis. This compound demonstrates significant biological activity in reducing inflammation and is suitable for various research applications focused on inflammatory processes. Its efficacy is noted in oral administration, facilitating its potential use in preclinical studies and therapeutic exploration. -
Anti-inflammatory Agent
Adelmidrol is an anti-inflammatory agent that primarily targets peroxisome proliferator-activated receptor gamma (PPARγ). This compound mediates significant reductions in NF-κB translocation and COX-2 expression, contributing to its anti-inflammatory effects. Adelmidrol is utilized in research focused on inflammation pathways and therapeutic potential in various inflammatory conditions. -
mPGES-1/5-LOX Inhibitor
YS121 is a dual inhibitor targeting microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LOX), with IC50 values of 3.4 μM and 6.5 μM, respectively. It demonstrates specific, reversible binding to mPGES-1, indicated by a KD of 10-14 μM. YS121 reduces PGE2 production in IL-1β-stimulated A549 cells with an EC50 of 12 μM and activates PPAR-α and PPAR-γ, with EC50 values of 1 μM and 3.6 μM, respectively. Additionally, YS121 exhibits significant anti-inflammatory effects in human whole blood and in vivo, making it a valuable tool for pleurisy research. -
Anti-Inflammatory Agent
3-Aminoisobutyric acid is an anti-inflammatory agent that exhibits both anti-inflammatory and antioxidant properties. It enhances the expression of genes associated with brown adipocytes in white adipose tissue and promotes fatty acid β-oxidation in hepatocytes. Additionally, 3-Aminoisobutyric acid mitigates insulin resistance and inflammation triggered by palmitate or a high-fat diet through an AMPK-PPARδ-dependent pathway in murine models. This compound also serves as a catabolic metabolite of thymine and valine within skeletal muscle, making it relevant for metabolic research. -
Anti-Inflammatory Agent
Romazarit, a PPARα agonist, serves as an effective anti-inflammatory agent with demonstrated antirheumatic properties. In studies, Romazarit has been shown to inhibit the development of hindpaw inflammation at a dosage of 30 mg/kg in an adjuvant arthritis model. This compound is of interest for research applications focusing on inflammatory diseases and therapeutic interventions in arthritis. -
Anti-inflammatory Agent
(3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside functions as an anti-inflammatory agent. This diarylheptanol glycoside, derived from Tacca plantaginea, effectively inhibits TNF-α-induced NF-κB transcriptional activity with an IC50 of 9.4 μM. Additionally, it activates PPAR transcriptional activity (EC50 = 9.9 μM) and exhibits a specific activating effect on PPAR β(δ) with an EC50 of 23.1 μM. Non-toxic to cells at tested concentrations, this compound is suitable for research on inflammatory conditions. -
COX-2 Inhibitor/PPAR-γ Activator
Zaltoprofen sulfoxide is a selective COX-2 inhibitor with an IC50 of 45.38 nM, as well as a PPAR-γ activator. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, making it a valuable tool in the study of inflammation and acute lung injury models. It is particularly relevant for research focused on LPS-induced acute lung injury. -
Antioxidant
Dihydrolipoic Acid (DHLA) is a potent antioxidant primarily targeting reactive oxygen species. It demonstrates significant anti-inflammatory effects across various disease models. Research indicates that DHLA can modulate the ERK/Nrf2/HO-1/ROS/NLRP3 signaling pathway, effectively mitigating sickness behavior in LPS-induced rat models. This compound is valuable for studies related to depression and oxidative stress-related disorders. -
Nrf2 Inhibitor
Nrf2-IN-3 is a small-molecule inhibitor targeting Nrf2 by enhancing the production of reactive oxygen species (ROS). It specifically binds to KEAP1 mutants, restoring their ability to inhibit Nrf2 and facilitating proteasome-dependent degradation of Nrf2 in cells. This compound has shown potential in sensitizing KEAP1-mutated tumor cells to chemotherapeutic agents such as Cisplatin and Gefitinib, making it a valuable tool for research in cancer therapeutics and Nrf2-related signaling pathways. -
Anti-inflammatory Agent
3-Demethylcolchicine is an anti-inflammatory agent known for its potent tubulin-binding activity. This colchicine metabolite effectively inhibits carrageenan-induced edema in rat paw models, making it valuable for research into inflammatory responses. Additionally, the presence of a hydroxyl group on its carbocyclic ring enhances its ability to scavenge free radicals, contributing to its therapeutic potential. 3-Demethylcolchicine serves as a key reagent in studies focused on inflammation and oxidative stress. -
COX-2 Inhibitor
Hexahydrocurcumin is a selective, orally active inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant potential in anti-inflammatory applications. As one of the primary metabolites of curcumin, it exhibits antioxidant and anticancer properties, making it relevant for research in various therapeutic areas. Its selectivity towards COX-2 over COX-1 highlights its potential for minimizing gastrointestinal side effects often associated with non-steroidal anti-inflammatory drugs (NSAIDs).
